Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseEndotoxin/LPSC57BL/6, including liver-specific G9a-deficient (L-G9a) mice and littermate controlsmale for D-galactosamine/lipopolysaccharide and acetaminophen experiments; male and female for lipopolysaccharide-only injectionrGSTP1 intravenous; BIX intraperitonealrGSTP1 10 mg/kg; BIX 50 mg/kg body weightrGSTP1 given 30 min before lipopolysaccharide or acetaminophen injection; BIX g…
Model: D-galactosamine (200 mg/kg body weight, intraperitoneal) plus lipopolysaccharide (3 mg/kg body weight, intraperitoneal) induced acute liver injury; and acetaminophen overdose (400 mg/kg body weight, intraperitoneal, after overnight fasting)
Liver-specific G9a deletion caused 100 per cent mortality after lipopolysaccharide under D-galactosamine sensitisation and worsened acetaminophen-induced injury, and treatment with recombinant GSTP1 reversed the liver damage in G9a-deficient mice, identifying a protective G9a-GSTP1 axis.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.